BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 153.2% in July

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 481,974 shares, an increase of 153.2% from the July 15th total of 190,323 shares. Approximately 4.1% of the company’s stock are sold short. Based on an average daily volume of 1,706,839 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC acquired a new position in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent filing with the Securities & Exchange Commission. 40.57% of the stock is owned by institutional investors and hedge funds.

BiomX Trading Up 4.5%

Shares of BiomX stock opened at $0.15 on Friday. The firm has a market capitalization of $1.83 million, a P/E ratio of -0.05 and a beta of 1.35. The business has a fifty day simple moving average of $0.33 and a two-hundred day simple moving average of $2.37. BiomX has a 12 month low of $0.12 and a 12 month high of $12.29.

BiomX (NYSEAMERICAN:PHGE) last released its earnings results on Wednesday, May 20th. The company reported $7.38 earnings per share for the quarter. Analysts predict that BiomX will post -5.85 earnings per share for the current year.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.